News Related to Neurocrine Biosciences

Related coverage linked through entity extraction aliases.

Laguna and Neurocrine advance schizophrenia diagnostic and treatment programs

May 02, 2026

Laguna won FDA Breakthrough Device Designation for a blood-based schizophrenia test, while Neurocrine dosed the first patient in a Phase 2 trial of NBI-1117570.

Neurocrine doses first patients in Phase 2 schizophrenia trial of NBI-1117570

Apr 13, 2026

Neurocrine Biosciences initiated and dosed the first patients in a Phase 2 trial of NBI-1117570 in adults with schizophrenia. Nxera Pharma said it will receive US$22.5 million in milestone payments to be recognised as Q1 FY2026 revenue.